우울 장애 시장 : 업계 동향과 세계 예측 - 우울증 유형별, 분자 유형별, 치료 유형별, 투여 경로별, 주요 지역별

Depressive Disorders Market: Industry Trends and Global Forecasts - Distribution by Type of Depression, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions

US $ 4,799 ￦ 6,650,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,699,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,688,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,943,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

우울 장애 시장 : 개요

세계의 우울 장애 시장 규모는 예측 기간 중 유리한 CAGR로 성장할 것으로 예측됩니다.

시장 세분화 및 기회 분석은 다음과 같은 매개 변수로 세분화됩니다.

우울증 유형

• 주요우울장애
• 양극성 장애
• 산후 우울증
• 치료 저항성 우울증
• 기타

분자 유형

• 저분자
• 생물제제

치료 유형

• 단독요법
• 병용요법
• 병용요법
• 순차요법

투여 경로

• 경구
• 비경구
• 비강
• 경피

주요 지역

• 북미
• 유럽
• 아시아태평양

우울장애 시장 : 성장과 동향

우울증은 끊임없는 슬픔과 외부 자극에 대한 무관심이 특징인 정신질환입니다. 이 만성질환은 전 세계에서 정신 장애의 주요 원인 중 하나로 여겨지고 있습니다. 실제로 전 세계에서 3억 명 이상의 모든 연령대의 사람들이 우울증을 앓고 있다는 사실은 주목할 만합니다. 또한 우울 장애는 미국에서 연간 약 2,100억 달러의 경제적 부담을 유발하는 것으로 추정됩니다. 우울증은 널리 퍼져 있고 큰 영향을 미치고 있음에도 불구하고 고소득 국가에서는 우울증 환자의 50% 이하만이 치료를 받고 있으며, 저소득 국가에서는 10% 이하로 떨어지고 있습니다. 그 결과, 수많은 브랜드 의약품과 150개 이상의 제네릭 의약품이 우울증 환자의 치료제로 FDA의 승인을 받았습니다. 제네릭 의약품과 다른 브랜드 의약품이 있음에도 불구하고 환자들은 더 나은 항우울제의 필요성에 대해 목소리를 높이고 있습니다.

그 결과, 더 나은 항우울제에 대한 수요가 증가함에 따라 이해관계자들은 우울증 치료를 위한 새로운 작용기전을 가진 중재 약물 및 약물/치료법 후보를 개발하기 위해 다양한 노력을 기울이고 있습니다. 최근 이해관계자들은 개별화 접근법에 의존하기 시작했으며, 경두개 직류 자극 요법(tDCS)과 케타민과 같은 새로운 치료법을 도입하고 장내 미생물과 우울증의 연관성을 탐구하고 있습니다.

우울장애 시장 : 주요 인사이트

이 보고서는 세계 우울장애 시장의 현황을 파악하고 산업내 잠재적인 성장 기회를 파악합니다. 이 보고서의 주요 조사 결과는 다음과 같습니다.

• 지난 수년간 우울장애 시장은 여러 임상 단계의 약물 실패를 경험했습니다. 보고된 다양한 이유 중 가장 흔한 것은 특정 임상 평가 변수를 달성하지 못한 것이 가장 흔한 이유였습니다.

• 현재 시장 상황은 세분화되어 있으며, 소규모 기업부터 대형 제약사까지 65개 이상의 우울증 치료제 후보물질이 개발되고 있습니다.
• 개발 파이프라인에 있는 일부 분자는 임상 개발 후기 단계에 있으며, 대부분의 약물은 단일 요법이며 경구 경로로 전달되도록 설계되어 있습니다.
• 다수의 시판 의약품과 탄탄한 임상 파이프라인을 통해 이 분야의 기회는 더 많은 제품 후보물질이 승인됨에 따라 꾸준히 확대될 것으로 예측됩니다.
• 대부분의 리드 분자는 단독요법으로 평가되고 있지만, 개발자들은 특정 약물을 보조요법이나 병용요법으로도 평가했습니다.
• 현재 우울증 치료제 파이프라인은 경구용 약물이 주류를 이루고 있지만, 비강이나 경피 등 다른 투여 경로도 연구되고 있습니다.
• 임상시험은 다양한 지역에서 등록되어 있지만, 북미에서 실시되는 임상시험이 가장 많으며, 임상시험의 70% 이상이 임상 II/III상 시험으로 평가되고 있습니다.
• 진화하는 제품 상황에 대응하기 위해 의약품 개발 기업은 후보물질이 임상적, 상업적으로 유능하다는 것을 보장하기 위해 많은 노력을 기울이고 있습니다.
• 2010년 이후 30억 달러 이상의 투자가 이루어졌고, 기업은 투자자들의 적극적인 지원을 받고 있습니다.
• Janssen Pharmaceutical, Lundbeck, Vistagen Therapeutics, Takeda Pharmaceutical Industry, Otsuka Pharmaceutical 등의 기업은 우울장애와 관련된 여러 계약을 체결한 바 있습니다.
• 총 금액의 약 60%는 지난 3년간 투자된 금액입니다. 특히 3월까지만 해도 이 분야 기업은 총 6억 5,000만 달러의 자금을 조달했습니다. 전체적으로는 28억 달러가 다양한 산업 이해관계자별 2차 공모를 통해 조달되었습니다.
• 이해관계자들은 제품 출시 주기의 여러 단계에 걸쳐 다양한 상업화 전략을 모색하고 있습니다. 특허 만료가 임박한 의약품의 경우, 개발자들은 수명주기관리 접근법을 채택할 것으로 예측됩니다.

우울 장애 시장의 참여 기업 예

• AbbVie
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly
• GSK
• H. Lundbeck
• Johnson & Johnson
• Merck
• Pfizer
• Sanofi

목차

제1장 서문

제2장 개요

제3장 서론

• 우울증과 우울 장애의 개요
• 우울증의 징후와 증상
• 우울증의 유형
• 우울증의 역학
• 우울증의 원인
• 우울증의 진단
• 현재의 치료 패러다임
• 혁신적인 치료 전략
• 향후 전망

제4장 파이프라인 리뷰 : 시판 및 임상 단계 의약품

• 챕터 개요
• 우울증 : 출시 및 개발 파이프라인
• 우울증 : 약제 개발자 리스트
• 우울증을 치료하는 기타 새로운 방법

제5장 사례 연구 : 중지된 의약품 개발 프로그램

• 챕터 개요
• 우울증 : 중지된 약제
• 우울증 : 중지된 임상시험
• 결론

제6장 파트너십과 협업

제7장 자금조달과 투자 분석

• 챕터 개요
• 자금조달의 유형
• 우울증 : 자금조달과 투자 분석
• 결론

제8장 임상시험 분석

• 챕터 개요
• 범위와 조사 방법
• 우울증 : 임상시험 분석
• 결론

제9장 임상시험 엔드포인트 분석

제10장 임상적 및 상업적 매력 분석

• 챕터 개요
• 조사 방법
• 임상적 및 상업적 매력 분석 : 우울증

제11장 주요 상업화 전략

• 챕터 개요
• 성공하는 의약품 발매 전략 : ROOTS 프레임워크
• 성공하는 의약품 발매 전략 : 제품 차별화
• 제품의 개발 단계에 따라 채택되는 상업화 전략
• 우울증 치료제로서 승인된 분자
  • Abilify Mycite(R)
  • Abilify Maintena(R)
  • Rexulti(R)
  • Vraylar (R)
  • Trintellix(R)
  • Fetzima(R)
  • Latuda(R)
  • Viibryd(R)
• 우울증 치료에 주력하는 기업이 채택하는 주요 상업화 전략
• 결론

제12장 우울증에 대한 디지털 치료법

• 챕터 개요
• 디지털 치료제의 개요
• 디지털 치료제의 개발과 상업화 경로
• 우울증에 대한 디지털 치료
  • 스탠드얼론 소프트웨어 애플리케이션
  • 퍼스널 코칭
  • AI 지원
  • 게임 솔루션
• 결론

제13장 결론

제14장 부록 1 : 표형식 데이터

제15장 부록 2 : 기업·단체 리스트

KSA

영문 목차

영문목차

DEPRESSIVE DISORDERS MARKET: OVERVIEW

As per Roots Analysis, the global depressive disorders market is anticipated to grow at a lucrative CAGR during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Depression

• Major Depression Disorder
• Bipolar Disorder
• Postpartum Depression
• Treatment-Resistant Depression
• Others

Type of Molecule

• Small Molecule
• Biologic

Type of Therapy

• Monotherapy
• Adjunctive Therapy
• Combination Therapy
• Sequential Therapy

Route of Administration

• Oral
• Parenteral
• Nasal
• Transdermal

Key Geographical Regions

• North America
• Europe
• Asia-Pacific

DEPRESSIVE DISORDERS MARKET: GROWTH AND TRENDS

Depression is a mental health disorder characterized by a constant feeling of sadness and lack of interest in external stimuli. Notably, this chronic condition is considered among the leading causes of mental disability worldwide. In fact, it is worth mentioning that, globally more than 300 million people of all age groups suffer from depression. Moreover, depressive disorders are estimated to cause an economic burden of approximately USD 210 billion in the US, annually. Despite its widespread occurrence and substantial impact, less than 50% of people with this condition receive treatment in high-income countries, and this number drops to less than 10% in low-income countries. As a result, a large number of branded drugs and over 150 generic products have been approved by the FDA to treat depression among patients. Despite the availability of generics and other branded drugs, patients have voiced the need for better antidepressants.

Consequently, the rising demand for better antidepressants has led stakeholders to undertake various initiatives to develop interventions and drug / therapy candidates with novel mechanism of action to treat depression. Recently, stakeholders have begun relying more on personalized approaches, incorporating new therapies, such as Transcranial Direct Current Stimulation (tDCS) and ketamine, and exploring the link between the gut microbiome and depression.

DEPRESSIVE DISORDERS MARKET: KEY INSIGHTS

The report delves into the current state of the global depressive disorders market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Over the past few years, the depressive disorders market has witnessed multiple clinical stage drug failures; amongst the various reported reasons, inability to achieve specific clinical endpoints was the most common.

• The current market landscape is fragmented, featuring small companies and established pharma giants, which are engaged in the development of over 65 drug candidates for treating different forms of depression.
• Several molecules in the development pipeline are in the late stages of clinical development; majority of the drugs are monotherapies and designed for delivery via oral route.
• With several marketed drugs and a healthy clinical pipeline, the opportunity in this domain is expected to evolve steadily as more product candidates get approved.
• Majority of the lead molecules are being evaluated as monotherapies; however, developers are also evaluating certain drugs as an adjunctive or combination therapy.
• Currently, the depressive drugs pipeline is dominated by orally administrable drugs; however, other routes of administration, such as nasal and transdermal, are also being investigated.
• Although clinical studies are registered across various geographies, maximum number of trials are being conducted in North America; over 70% of clinical trials are evaluating drugs in Phase II / Phase III.
• In lieu of the evolving product landscape, drug developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent.
• A substantial proportion of partnerships in this domain are focused on digital therapeutics initiatives; with over USD 3 billion investments since 2010, companies have received active support from investors.
• Companies, such as Janssen Pharmaceutical, Lundbeck, Vistagen Therapeutics, Takeda Pharmaceutical and Otsuka Pharmaceutical, have signed multiple deals related to depressive disorders; majority of the aforementioned agreements were signed for R&D purpose.
• Around 60% of the total amount was invested in the last three years. Specifically, till March alone, companies engaged in this domain had collectively raised USD 650 million. Overall, a sum of USD 2.8 billion was raised by various industry stakeholders through secondary offerings.
• Stakeholders are exploring diverse commercialization strategies across different stages of a product's launch cycle; with drugs nearing patent expiry, developers are expected to adopt lifecycle management approaches.

Example Players in the Depressive Disorders Market

• AbbVie
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly
• GSK
• H. Lundbeck
• Johnson & Johnson
• Merck
• Pfizer
• Sanofi

DEPRESSIVE DISORDERS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the depressive disorders market, focusing on key market segments, including [A] type of depression, [B] type of molecule, [C] type of therapy, [D] route of administration and [E] key geographical regions.
• Market Landscape: A comprehensive evaluation of market landscape, based on several relevant parameters, such as [A] information on drug developer(s), [B] phase of development, [C] type of molecule, [D] type of therapy, [E] type of depression, [F] type of drug class, [G] mechanism of action, [H] dosing frequency and [I] route of administration.
• Discontinued Drug Development Programs Case Study: In-depth assessment of discontinued drugs / trials, focusing on [A] the number of discontinued drug development programs, [B] year of discontinuation, [C] geographical location, [D] phase at which the development program was discontinued, [E] mechanism of action of discontinued drug, [F] disease indication, [G] reason(s) for discontinuation and [H] information on affiliated developer companies.
• Partnerships and Collaborations: A detailed analysis of the deals inked by stakeholders in this domain, based on various parameters, such as [A] year of partnership, [B] type of partnership, [C] area of focus, [D] type of depressive disorder, [E] geography and [F] most active players.
• Fundings and Investments: An in-depth analysis of the fundings received by players in depressive disorders domain, based on relevant parameters, such as [A] number of funding instances, [B] amount invested, [C] type of funding, [D] most active players, [E] most active investors and [F] geography.
• Clinical Trial Analysis: An insightful analysis of clinical trials related to depressive disorders, based on several parameters, such as [A] trial registration year, [B] current trial status, [C] current trial phase, [D] type of depressive disorder, [E] mechanism of action, [F] leading industry and non-industry players with highest number of completed / ongoing trials, [G] regional distribution of clinical trials and [H] enrolled patient population across different geographies.
• Clinical Trial Endpoints Analysis: A detailed analysis of the clinical endpoints in late-stage ongoing and planned studies, for various types of depressive disorders.
• Clinical and Commercial Attractiveness Analysis: A comprehensive assessment of clinical and commercial attractiveness of pipeline molecules based on several parameters, such as [A] size of enrolled patient population, [B] route of administration, [C] therapy type and dosing frequency, [D] target patient population, [E] expected launch date and [F] size of developer company.
• Key Commercialization Strategies: A detailed discussion on the various strategies that can be adopted by the drug developers across key commercialization stages including a timeline representation of the key strategies adopted.
• Digital Therapeutics for Depressive Disorders Case Study: A detailed discussion on the upcoming digital health solutions for the management / treatment of depression, featuring information on the various product development pathways adopted by companies involved in this segment of the market.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. An Overview of Depression and Depressive Disorders
• 3.2. Signs and Symptoms of Depression
• 3.3. Types of Depression
• 3.4. Epidemiology of Depression
• 3.5. Causes of Depression
• 3.6. Diagnosis of Depression
• 3.7. Current Treatment Paradigms
  • 3.7.1. Pharmacological Treatment
  • 3.7.2. Psychological Treatment
  • 3.7.3. Other Treatments
• 3.8. Innovative Therapeutic Strategies
• 3.9. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL STAGE DRUGS

• 4.1. Chapter Overview
• 4.2. Depressive Disorders: Marketed and Development Pipeline
  • 4.2.1. Analysis by Phase of Development
  • 4.2.2. Analysis by Type of Depressive Disorder
  • 4.2.3. Analysis by Type of Therapy
  • 4.2.4. Analysis by Type of Molecules
  • 4.2.5. Analysis by Route of Administration
  • 4.2.6. Analysis by Dosing Frequency
  • 4.2.7. Analysis by Type of Drug and Drug Class
  • 4.2.8. Major Depressive Disorder
    • 4.2.8.1. Analysis by Phase of Development
    • 4.2.8.2. Analysis by Route of Administration
    • 4.2.8.3. Analysis by Dosing Frequency
    • 4.2.8.4. Key Players
  • 4.2.9. Bipolar Disorder / Bipolar Depression
    • 4.2.9.1. Analysis by Phase of Development
    • 4.2.9.2. Analysis by Route of Administration
    • 4.2.9.3. Analysis by Dosing Frequency
    • 4.2.9.4. Key Players
  • 4.2.10. Treatment-Resistant Depression
    • 4.2.10.1. Analysis by Phase of Development
    • 4.2.10.2. Analysis by Route of Administration
    • 4.2.10.3. Analysis by Dosing Frequency
    • 4.2.10.4. Key Players
  • 4.2.11. Postpartum Depression and Depression (Type Unknown)
    • 4.2.11.1. Analysis by Phase of Development
    • 4.2.11.2. Analysis by Route of Administration
    • 4.2.11.3. Analysis by Dosing Frequency
    • 4.2.11.4. Key Players
  • 4.2.12 Grid Analysis: Distribution by Phase of Development, Type of Depressive Disorder and Type of Drug
• 4.3. Depressive Disorders: List of Drug Developers
  • 4.3.1. Analysis by Year of Establishment of Developers
  • 4.3.2. Analysis by Company Size
  • 4.3.3. Analysis by Geographical Location of Developers
  • 4.3.4. Analysis by Type of Depressive Disorder
  • 4.3.5. Key Developers
  • 4.3.6. Grid Analysis: Distribution by Location of Developer, Company Size and Type of Depressive Disorder
• 4.4 Other Novel Ways to Treat Depression
  • 4.4.1. Role of Neurostimulation Devices
  • 4.4.2. Role of Microbiome Therapeutics

5. CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS

• 5.1. Chapter Overview
• 5.2. Depressive Disorders: Discontinued Drugs
  • 5.2.1. Analysis by Year of Discontinuation
  • 5.2.2. Analysis by Phase of Discontinuation
  • 5.2.3. Analysis by Mechanism of Action
  • 5.2.4. Analysis by Type of Depressive Disorder
  • 5.2.5. Key Players
  • 5.2.6. Analysis by Reason for Discontinuation
• 5.3. Depressive Disorders: Discontinued Clinical Trials
  • 5.3.1. Year-wise Trend of Discontinued Trials
  • 5.3.2. Analysis of Discontinued Clinical Trials by Phase of Development
  • 5.3.3. Analysis of Discontinued Clinical Trials by Sponsor / Collaborator
  • 5.3.4. Analysis of Discontinued Clinical Trials by Geography
  • 5.3.5. Analysis of Discontinued Clinical Trials by Reason of Discontinuation
• 5.4. Concluding Remarks

6. PARTNERSHIPS AND COLLABORATIONS

• 6.1. Chapter Overview
• 6.2. Partnership Models
• 6.3. Depressive Disorders: List of Partnerships and Collaborations
  • 6.3.1. Analysis by Year of Partnerships
  • 6.3.2. Analysis by Type of Partnership
  • 6.3.3. Analysis by Type and Year pf Partnership
  • 6.3.4. Analysis by Area of Focus
  • 6.3.5. Analysis by Type of Depressive Disorder
  • 6.3.6. Regional Analysis
    • 6.3.6.1. Local and International Agreements
    • 6.3.6.2. Intercontinental and Intracontinental Agreements
  • 6.3.7. Most Active Players: Analysis by Number of Partnerships
  • 6.3.8. Big Pharma Players

7. FUNDING AND INVESTMENT ANALYSIS

• 7.1. Chapter Overview
• 7.2. Types of Funding
• 7.3. Depressive Disorders: Funding and Investment Analysis
  • 7.3.1. Analysis by Number of Instances
  • 7.3.2. Analysis by Amount Invested
  • 7.3.3. High Value Deals: Analysis by Year
  • 7.3.4. Analysis by Type of Funding
  • 7.3.5. Analysis by Number of Funding Instances across Different Therapeutic Areas
  • 7.3.6. Most Active Players
  • 7.3.7. Most Active Investors
• 7.4. Concluding Remarks

8. CLINICAL TRIAL ANALYSIS

• 8.1. Chapter Overview
• 8.2. Scope and Methodology
• 8.3. Depressive Disorders: Clinical Trial Analysis
  • 8.3.1. Analysis by Trial Registration Year
  • 8.3.2. Analysis by Trial Phase
  • 8.3.3. Analysis by Recruitment Status
  • 8.3.4. Analysis by Type of Sponsor / Collaborator
  • 8.3.5. Analysis by Type of Depressive Disorder
  • 8.3.6. Analysis by Type of Drug Class
  • 8.3.7. Most Active Players
  • 8.3.8. Analysis by Number of Clinical Trials and Geography
  • 8.3.9. Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
  • 8.3.10. Analysis by Number of Clinical Trials, Type of Depressive Disorder and Geography
  • 8.3.11. Analysis by Number of Clinical Trials, Type of Depressive Disorder, Trial Phase and Geography
  • 8.3.12. Analysis by Number of Clinical Trials, Type of Drug Class and Geography
  • 8.3.13. Analysis by Number of Clinical Trials, Type of Drug Class, Trial Phase and Geography
  • 8.3.14. Analysis by Enrolled Patient Population and Geography
  • 8.3.15. Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status
  • 8.3.16. Analysis by Enrolled Patient Population, Type of Depressive Disorder and Geography
  • 8.3.17. Analysis by Enrolled Patient Population, Type of Depressive Disorder, Trial Phase and Geography
  • 8.3.18. Analysis by Enrolled Patient Population, Type of Drug Class and Geography
  • 8.3.19. Analysis by Enrolled Patient Population, Type of Drug Class, Trial Phase and Geography
• 8.4. Concluding Remarks
  • 8.4.1. Emerging Molecules to Watch
  • 8.4.2. Most Important Trials to Watch

9. CLINICAL TRIAL ENDPOINTS ANALYSIS

• 9.1. Chapter Overview
• 9.2. Scope and Methodology
• 9.3. Overview of the Most Common Primary Endpoints
• 9.4. Primary Endpoints Evaluated for Major Depressive Disorder: Comparative Analysis of Late-Stage Drugs
• 9.5. Primary Endpoints Evaluated for Bipolar Disorder: Comparative Analysis of Late-Stage Drugs
• 9.6. Primary Endpoints Evaluated for Other Types of Depressive Disorder: Comparative Analysis of Late-Stage Drugs

10. CLINICAL AND COMMERCIAL ATTRACTIVENESS ANALYSIS

• 10.1. Chapter Overview
• 10.2. Methodology
  • 10.2.1. Assumptions and Key Parameters
• 10.3. Clinical and Commercial Attractiveness Analysis: Depressive Disorders
  • 10.3.1. Clinical and Commercial Attractiveness Analysis: Major Depressive Disorder
  • 10.3.2. Clinical and Commercial Attractiveness Analysis: Bipolar Disorder
  • 10.3.3. Clinical and Commercial Attractiveness Analysis: Other Types of Depressive Disorder

11. KEY COMMERCIALIZATION STRATEGIES

• 11.1. Chapter Overview
• 11.2. Successful Drug Launch Strategy: ROOTS Framework
• 11.3. Successful Drug Launch Strategy: Product Differentiation
• 11.4. Commercialization Strategies Adopted Based on Development Stage of Product
• 11.5. Approved Molecules for Treating Depressive Disorders
  • 11.5.1. Abilify Mycite(R)
  • 11.5.2. Abilify Maintena(R)
  • 11.5.3. Rexulti(R)
  • 11.5.4. Vraylar (R)
  • 11.5.5. Trintellix(R)
  • 11.5.6. Fetzima(R)
  • 11.5.7. Latuda(R)
  • 11.5.8. Viibryd(R)
• 11.6. Key Commercialization Strategies Adopted by Companies Focused on Depressive Disorders
  • 11.6.1. Strategies Adopted Before the Approval of Drug
    • 11.6.1.1. Participation in Global Events
  • 11.6.2. Strategies Adopted During the Launch of Drug
    • 11.6.2.1. Collaboration with Internal Stakeholders and Pharmaceutical Firms
    • 11.6.2.2. Awareness through Product Websites
    • 11.6.2.3. Direct to Consumer (DTC) Advertisements
  • 11.6.3. Strategies Adopted Post Drug Launch / Near Patent Expiry of Drug
    • 11.6.3.1. Approval of Drug in Multiple Geographies
    • 11.6.3.2. Approval of Drug for Multiple Indications
• 11.7. Concluding Remarks

12. DIGITAL THERAPEUTICS FOR DEPRESSIVE DISORDERS

• 12.1. Chapter Overview
• 12.2. An Overview of Digital Therapeutics
• 12.3. Development and Commercialization Pathway for Digital Therapeutics
  • 12.3.1. Discovery and Preclinical Research
  • 12.3.2. Clinical Trials and Validation
  • 12.3.3. Engaging Insurance Providers / Payers
  • 12.3.4. Distribution and Marketing
• 12.4. Digital Therapeutics for Depressive Disorders
  • 12.4.1. Standalone Software Applications
  • 12.4.2. Personal Coaching
  • 12.4.3. AI Support
  • 12.4.4. Gaming Solutions
• 12.5. Concluding Remarks

13. CONCLUDING REMARKS

• 13.1. Chapter Overview
• 13.2. Key Takeaways

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료